Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know

IN BRIEF Titratable fixed-ratio combinations (FRCs) of a basal insulin and a glucagon-like peptide-1 (GLP-1) receptor agonist are new therapeutic options for people with type 2 diabetes. Two FRCs—insulin degludec/liraglutide and insulin glargine/lixisenatide—have been approved for use in the United...

Descripción completa

Detalles Bibliográficos
Autores principales: Skolnik, Neil, Hinnen, Debbie, Kiriakov, Yan, Magwire, Melissa L., White, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2018
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898172/
https://www.ncbi.nlm.nih.gov/pubmed/29686457
http://dx.doi.org/10.2337/cd17-0048
_version_ 1783314089879011328
author Skolnik, Neil
Hinnen, Debbie
Kiriakov, Yan
Magwire, Melissa L.
White, John R.
author_facet Skolnik, Neil
Hinnen, Debbie
Kiriakov, Yan
Magwire, Melissa L.
White, John R.
author_sort Skolnik, Neil
collection PubMed
description IN BRIEF Titratable fixed-ratio combinations (FRCs) of a basal insulin and a glucagon-like peptide-1 (GLP-1) receptor agonist are new therapeutic options for people with type 2 diabetes. Two FRCs—insulin degludec/liraglutide and insulin glargine/lixisenatide—have been approved for use in the United States. The two components in these FRCs target different aspects of diabetes pathophysiology, working in a complementary manner to decrease blood glucose while mitigating the side effects associated with each component (hypoglycemia and weight gain with insulin and gastrointestinal side effects with GLP-1 receptor agonists). This article reviews these products and key considerations for their use.
format Online
Article
Text
id pubmed-5898172
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-58981722019-04-01 Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know Skolnik, Neil Hinnen, Debbie Kiriakov, Yan Magwire, Melissa L. White, John R. Clin Diabetes Feature Articles IN BRIEF Titratable fixed-ratio combinations (FRCs) of a basal insulin and a glucagon-like peptide-1 (GLP-1) receptor agonist are new therapeutic options for people with type 2 diabetes. Two FRCs—insulin degludec/liraglutide and insulin glargine/lixisenatide—have been approved for use in the United States. The two components in these FRCs target different aspects of diabetes pathophysiology, working in a complementary manner to decrease blood glucose while mitigating the side effects associated with each component (hypoglycemia and weight gain with insulin and gastrointestinal side effects with GLP-1 receptor agonists). This article reviews these products and key considerations for their use. American Diabetes Association 2018-04 /pmc/articles/PMC5898172/ /pubmed/29686457 http://dx.doi.org/10.2337/cd17-0048 Text en © 2018 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0 for details.
spellingShingle Feature Articles
Skolnik, Neil
Hinnen, Debbie
Kiriakov, Yan
Magwire, Melissa L.
White, John R.
Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
title Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
title_full Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
title_fullStr Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
title_full_unstemmed Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
title_short Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
title_sort initiating titratable fixed-ratio combinations of basal insulin analogs and glucagon-like peptide-1 receptor agonists: what you need to know
topic Feature Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898172/
https://www.ncbi.nlm.nih.gov/pubmed/29686457
http://dx.doi.org/10.2337/cd17-0048
work_keys_str_mv AT skolnikneil initiatingtitratablefixedratiocombinationsofbasalinsulinanalogsandglucagonlikepeptide1receptoragonistswhatyouneedtoknow
AT hinnendebbie initiatingtitratablefixedratiocombinationsofbasalinsulinanalogsandglucagonlikepeptide1receptoragonistswhatyouneedtoknow
AT kiriakovyan initiatingtitratablefixedratiocombinationsofbasalinsulinanalogsandglucagonlikepeptide1receptoragonistswhatyouneedtoknow
AT magwiremelissal initiatingtitratablefixedratiocombinationsofbasalinsulinanalogsandglucagonlikepeptide1receptoragonistswhatyouneedtoknow
AT whitejohnr initiatingtitratablefixedratiocombinationsofbasalinsulinanalogsandglucagonlikepeptide1receptoragonistswhatyouneedtoknow

Ejemplares similares